Compare CAVA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAVA | GKOS |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 6.0B |
| IPO Year | 2023 | 2015 |
| Metric | CAVA | GKOS |
|---|---|---|
| Price | $83.67 | $118.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 14 |
| Target Price | $88.67 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 2.7M | 652.5K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,179,664,000.00 | $507,442,000.00 |
| Revenue This Year | $25.71 | $23.30 |
| Revenue Next Year | $20.50 | $27.43 |
| P/E Ratio | $157.24 | ★ N/A |
| Revenue Growth | 22.41 | ★ 32.33 |
| 52 Week Low | $43.41 | $73.16 |
| 52 Week High | $97.98 | $130.23 |
| Indicator | CAVA | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 60.82 |
| Support Level | $83.50 | $104.72 |
| Resistance Level | $90.84 | $123.16 |
| Average True Range (ATR) | 4.05 | 4.52 |
| MACD | -0.02 | 1.61 |
| Stochastic Oscillator | 65.49 | 80.42 |
Cava Group Inc owns and operates a chain of restaurants. It operates a Mediterranean-inspired fast-casual restaurant brand offering menu items. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: i) CAVA: It includes the operations of all company-owned CAVA restaurants, and ii) CAVA Foods: It includes the production of dips, spreads, and certain dressing bases used in CAVA restaurants as well as sales from the Company's consumer packaged goods business. The company generates the majority of its revenue from the CAVA segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.